Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.68 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.61 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.49 |
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20847726 | 0.84 | KCNA5 (0.68) | HDAC6HDAC8HDAC11KCNA5TAS2R14 | |
| SCHEMBL20847763 | 0.77 | TAS2R14 (0.59) | HDAC6HDAC8HDAC11KCNA5TAS2R14 | |
| SCHEMBL22482734 | 0.76 | HDAC6 (1.00) | HDAC6HDAC8HDAC11 | |
| SCHEMBL20847569 | 0.74 | HDAC6 (0.65) | HDAC6HDAC8HDAC11KCNA5 | |
| SCHEMBL22482900 | 0.74 | HDAC6 (0.70) | HDAC6HDAC8HDAC11TAS2R14 | |
| SCHEMBL29671340 | 0.74 | APLNR (0.61) | HDAC6HDAC8HDAC11TAS2R14CNR1 | |
| SCHEMBL20847564 | 0.74 | HDAC6 (0.62) | HDAC6HDAC8HDAC11 | |
| SCHEMBL20847691 | 0.73 | HDAC6 (0.58) | HDAC6HDAC8HDAC11KCNA5TAS2R14 | |
| SCHEMBL16700339 | 0.73 | MMP13 (0.46) | — | |
| SCHEMBL20847659 | 0.72 | HDAC6 (0.67) | HDAC6HDAC8HDAC11KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200277268-A1 | PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | DALRIADA THERAPEUTICS INC. (CA) | 2020-09-03 | — | — | US | disclosed |
| WO-2019056120-A1 | PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | DALRIADA THERAPEUTICS INC. (CA) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277268-A1 | PENTAFLUOROPHENYL SULFONAMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | MKI67, PKD1, ETV6 | HDAC6 499/4885HDAC8 1916/4885HDAC11 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.